Founders ask “what is my startup worth?” as if there’s a single correct answer sitting in a spreadsheet somewhere. There isn’t. Startup valuation is a negotiation informed by method, market context, and the specific investor across the table from you. The number you arrive at matters — it determines your dilution, your future round headroom, and how much of your own company you take home at exit. Getting it wrong in either direction costs you.
This guide covers the methods that actually get used in 2026: what applies before you have revenue, what applies after, and how to understand the VC math that underpins every term sheet you’ll ever receive.
Why Valuation Matters More Than Founders Think
Every funding round sells a percentage of your company. The valuation sets that percentage.
Raise $500K at a $5M pre-money valuation, and the investor owns about 9.1% post-money. Raise the same $500K at a $2.5M pre-money valuation, and they own about 16.7%. Same check. Dramatically different outcome for you, compounded across every round that follows. A founder who gets squeezed on valuation in a seed round enters a Series A with less leverage, more dilution pressure, and less room to attract future capital on favorable terms.
Valuation also cascades forward. Setting an artificially high valuation to win a round sounds smart until the next round requires demonstrating enough growth to justify a higher number. Founders who overprice a seed wind up doing flat or down rounds at Series A — and the signals that sends to the market are punishing.
The goal isn’t to maximize your valuation in a vacuum. It’s to get to a number that’s defensible, fair given your stage and traction, and sets up the next round well.
The Stage Problem: One Method Does Not Fit All
Valuation methodology depends almost entirely on where you are. A company with $2M ARR and 120% net revenue retention gets valued differently than a company with a prototype and three letters of intent. Conflating the methods — or applying a revenue-multiple framework to a pre-revenue company — produces a number with no basis in how investors actually think.
The clean division is pre-revenue and post-revenue. Within each, there are a few methods that matter.
Pre-Revenue Valuation: Making Defensible Estimates Without Data
Pre-revenue companies have no financial history to discount or multiply. Every method at this stage is really a structured way to translate qualitative factors into a number. The quality of the method is the quality of the inputs.
The Berkus Method
Developed by angel investor Dave Berkus, this assigns a dollar range to five risk factors: the soundness of the core idea, the quality of the prototype or MVP, the caliber of the management team, existing strategic relationships, and early product rollout or sales.
Each factor can contribute up to $500K–$1M to the valuation (the original model caps at $2M total; updated versions stretch to $2.5M or higher for software). The total of the five ranges becomes the pre-money valuation.
Berkus is widely used in angel rounds because it is transparent, teachable, and forces a structured conversation about the real risks. Its weakness: the ranges are inherently subjective, and investors will have their own read on how much each factor is worth.
The Scorecard Method
The Scorecard method (also called the Bill Payne method) starts from a baseline: the average pre-money valuation for comparable seed-stage companies in your sector and geography. It then multiplies that baseline by a weighted set of factors.
A typical weighting looks like:
- Strength of the management team: 30%
- Size of the opportunity: 25%
- Product / technology: 15%
- Competitive environment: 10%
- Marketing / sales channels / partnerships: 10%
- Need for additional investment: 5%
- Other factors: 5%
Each factor is rated relative to a typical comparable company (1.0 = average, 1.25 = strong, 0.75 = weak). Multiply the baseline by the composite score. The result is your valuation estimate.
The Scorecard method is more grounded than Berkus because it anchors to real market data — but only if you have reliable comparable data for your sector and stage. In markets where deal data is scarce, that anchor is hard to find.
Risk Factor Summation
This method starts from a baseline (same as Scorecard) and adjusts up or down based on twelve risk factors: management, stage of the business, legislation/political risk, manufacturing risk, sales and marketing risk, funding/capital raising risk, competition risk, technology risk, litigation risk, international risk, reputation risk, and potential lucrative exit. Each factor contributes a fixed increment (often +$250K for positive, −$250K for negative) to the baseline.
Risk Factor Summation is more comprehensive than the Scorecard but more cumbersome to explain in a room. Most angel groups use it internally rather than presenting it to founders.
Post-Revenue Valuation: Where the Math Gets Cleaner
Once a company has recurring revenue — particularly predictable, subscription-based ARR — valuation moves from estimation to comparison. The core question becomes: what are comparable companies in this space, at this stage, trading at?
Revenue Multiples (ARR or MRR × Multiple)
For SaaS and recurring-revenue businesses, the primary method is simple: valuation = ARR × multiple. The multiple reflects growth rate, net revenue retention, margin profile, market size, and competitive moat.
In 2026, after several years of multiple compression following the rate environment that cratered 2021–2022 valuations, the private market multiples for early-stage SaaS have roughly stabilized. Broad benchmarks:
- Pre-Seed / Seed (sub-$1M ARR): 5–15× ARR, heavily weighted by team, growth velocity, and market size rather than pure revenue.
- Series A ($1M–$5M ARR): 8–20× ARR for companies with strong growth (100%+ YoY) and healthy NRR (110%+). Lower multiples for slower growers.
- Series B+ ($5M+ ARR): 10–25× ARR for best-in-class; 4–10× for the median. Growth rate is the dominant variable.
These ranges are medians and averages — individual deals diverge significantly based on investor competition, category narrative, and founder leverage. A company growing 200% YoY in a hot category commands a premium. A company growing 40% in a crowded market gets discounted.
The key variable inside the multiple is net revenue retention (NRR). NRR above 110–120% — meaning existing customers expand faster than they churn — is the single metric that most reliably justifies a premium multiple. It is proof that the product gets more valuable as customers use it.
Comparable Transactions
Alongside multiples, investors triangulate against actual deal data: what did comparable companies in this space raise at, recently, and at what valuation?
Founders often don’t have access to private deal data directly, but the information moves through investor networks, founders who’ve recently raised, and databases like PitchBook or Crunchbase (behind a paywall for precise terms, but useful for ranges). Your investors have this data — knowing that the last three companies in your space raised Series A rounds at 12–15× ARR helps you walk into the negotiation with a realistic anchor.
DCF (Discounted Cash Flow): Why It Rarely Applies to Early-Stage Startups
DCF — discounting projected future cash flows back to present value — is theoretically the most rigorous method. In practice, it is almost never the primary method for early-stage startup valuation, for a simple reason: the projections are too speculative to be meaningful. Discount rates for startups range from 40–80%, reflecting the high probability of failure, which collapses any reasonable multi-year cash flow forecast to a negligible present value.
DCF appears in later-stage or growth equity deals where the company has years of financial history and more predictable trajectories. For seed and Series A, it’s a secondary check at best.
How VCs Actually Arrive at Valuations
Understanding how professional investors set valuations gives you real negotiating leverage. The key insight: VCs work backwards from ownership targets, not forwards from an objective assessment of your company’s worth.
Here’s the math. A typical early-stage VC fund needs to return 3–5× its fund capital to its limited partners. For a $100M fund, that means returning $300–$500M. Because most portfolio companies fail or return minimal capital, the model requires a few large winners to carry the fund.
To get a 3× return on a $100M fund, the fund needs to return roughly $300M in distributed proceeds. If the fund has 30 companies, and the top 5 must carry 80% of returns, each winner needs to return ~$48M in proceeds. For a company that exits at $200M, the fund needs to own ~24% at exit to hit that number.
Working backwards: if the fund targets ~20–25% ownership at exit, and assumes 2× dilution from future rounds, it needs to own 40–50% post-money at entry. That ownership target, not your company’s intrinsic worth, drives the valuation math.
This is why investors say “the valuation follows the check size.” If a fund writes $2M checks and targets 20% post-money ownership, the math implies a $10M pre-money valuation regardless of your growth rate — unless you can credibly command otherwise.
Knowing this, founders can work backwards too: if you’re raising $2M and you think a fair ownership stake is 15%, you need to defend a $13.3M pre-money valuation. Knowing the investor’s ownership math helps you understand whether their offer is fund-formula or genuinely reflects your company.
Common Mistakes Founders Make
Anchoring to a round size, not a valuation. “We’re raising $1.5M” is not a valuation. Specify the pre-money valuation you’re targeting, so you know exactly what ownership you’re selling.
Conflating post-money with enterprise value. The post-money valuation is a venture convention, not a market appraisal. A company valued at $8M post-money seed is not necessarily sellable for $8M — it reflects what a single investor paid for a small stake under specific terms.
Setting valuation based on financial projections. Investors don’t buy your projections; they price your traction. A projection-based valuation argument (“we’ll be at $5M ARR in three years, so we’re worth $50M today”) is almost never convincing as a primary anchor.
Pricing too high for the stage. A seed-stage company with $100K in ARR priced at $15M pre-money creates a difficult Series A bar: you need to 10× to justify a $30M A at a reasonable multiple. Founders sometimes win a high seed valuation and lose the next round.
Ignoring the cap table. Valuation is not the only term that determines your economics. Liquidation preferences, participation rights, and anti-dilution provisions can all reduce founder proceeds at exit even when the valuation looked favorable at close. Brad Feld and Jason Mendelson cover the full mechanics in Venture Deals — one of the few books that actually explains how these terms interact in practice.
What Investors Will Ask You to Justify
At any fundraising conversation, come prepared to defend your valuation on at least three of these dimensions:
- Comparable transactions: What have similar companies at your stage raised at, and why should your company command parity or a premium?
- Revenue multiple: If you have ARR, what multiple is implied by your ask, and why does your growth and NRR justify it?
- Market opportunity: Is the TAM large enough that a venture-scale outcome is credible? Investors need to believe a path to 10× exists.
- Team: Do you have domain expertise, prior wins, or unique access that reduces the execution risk?
- Traction trajectory: Is growth accelerating or decelerating? A company growing 15% month-over-month commands different pricing than one growing 5%.
You don’t need a perfect answer to all five. But you need a story that holds up on the dimensions most relevant to your stage.
A Quick Valuation Framework by Stage
| Stage | Method | What investors weight most |
|---|---|---|
| Pre-product / idea | Berkus, Risk Factor Summation | Team, market size |
| MVP / early users | Scorecard, comparable transactions | Team, early signal |
| Pre-revenue with strong LOIs | Scorecard + comparable | Team, strategic relationships |
| $100K–$500K ARR | ARR multiple (5–12×) + comps | Growth rate, early retention |
| $500K–$2M ARR | ARR multiple (8–18×) + comps | NRR, growth rate, GTM efficiency |
| $2M+ ARR | ARR multiple + DCF check | NRR, margin, competitive position |
FAQ
How do I know what multiple my ARR deserves?
Growth rate is the dominant variable. A rule of thumb: your multiple approximates your growth rate as a percentage. Growing 150% YoY suggests a 10–15× multiple might be defensible; growing 50% YoY suggests closer to 5–8×. Adjust up for outstanding NRR, strong competitive moat, or category leadership; down for margin weakness, concentrated customer risk, or founder-dependent revenue.
Should I always maximize my valuation?
No. A too-high valuation creates a steeper bar for your next round, signals desperation or inexperience if the number isn’t grounded, and can strain your investor relationship if growth disappoints. A fair valuation that closes the round quickly, preserves future optionality, and sets a realistic A-round bar is worth more than a stretched number that barely closes.
What does pre-money vs. post-money valuation mean?
Pre-money valuation is your company’s value before new investment arrives. Post-money is pre-money plus the capital raised. If you’re valued at $8M pre-money and raise $2M, your post-money valuation is $10M and the investor owns 20%. Watch out: some term sheets express valuations as post-money (especially SAFEs with post-money caps) — the dilution math looks different.
Do SAFE notes have a valuation?
SAFEs (Simple Agreements for Future Equity) typically include a valuation cap — the maximum conversion price if the company raises a priced round. If your SAFE has a $6M cap and you raise a Series A at a $15M pre-money valuation, SAFE holders convert at $6M, getting more shares than Series A investors. Understanding cap math before you issue SAFEs is critical to avoiding a cap table surprise at your priced round.
How long does a typical valuation negotiation take?
For angel rounds, often one to three weeks of conversation after initial interest. For institutional seed or Series A, the formal diligence process runs four to eight weeks from term sheet to close. Valuation is usually agreed early in the process — it’s the downstream terms (option pool, preferences, board seats) where negotiation extends.
Valuation is not mystical. It is a structured negotiation between what you can defend with data and story, and what an investor needs to make their fund math work. Founders who understand both sides of that equation — their traction, their comparables, and the ownership arithmetic their investor is working backwards from — close better rounds on better terms.
For more on how the underlying deal terms interact with your valuation, the most useful resource is still Venture Deals by Brad Feld and Jason Mendelson — it explains the full machinery of a VC financing in plain language. For more on the decision of whether to raise at all, see our breakdown of bootstrapping vs. venture capital in 2026.
